Till startsida
University of Gothenburg
To content Read more about how we use cookies on gu.se

Group Ola Nilsson

Research summary

Neuroendocrine (NE) tumours (carcinoids, pheochromocytoma, medullary thyroid carcinoma (MTC)) usually present with hormonal symptoms due to distant metastases. There is need for a better understanding of pathogenetic mechanisms and prognostic factors in NE tumours as well as novel treatment options. Somatostatin receptors (SSTR) are highly expressed, which allows scintigraphic imaging via radiolabelled somatostatin analogs. SSTR-mediated radiotherapy is one novel treatment option for NE tumours.

Ongoing projects:

1. Profiling NE tumours by CGH, mRNA and siRNA arrays as well as by exome sequencing, to identify genetic changes and activated signaling pathways that can serve as targets for therapy.

2. Charactising CSC in carcinoid tumours by fluorescent-activated cell sorting (FACS) with respect to cell populations capable of self-renewal and tumour initiation.

3. Pyridylcyanoguanidines as inhibitors of NFkB/Rel transcription factors and NADsynthesis via the PARP enzymes. This effect is additive to radiation-induced DNA damage and suggests pyridylcyanoguanidines as radiosensitizers to SSTR-mediated radiotherapy.

4. Valproic acid - activator of Notch-1 and inhibitor of HDAC. An anti-epileptic drug with established safety profile induces apoptosis and retards the growth of tumour xenografts - may soon go into international phase II trials.

5. Enhancing the NET transporter to increase the efficacy of 131-I-MIBG-therapy by pretreatment with cisplatin or topoisomerase inhibitors.

6. Clinical projects on carcinoid heart disease, new prognosticators for midgut carcinoids (including transplantation as treatment), phenotypic expression associated with RET mutations in hereditary MTC and treatment with TKI, response of hereditary and sporadic pheochromocytomas to sunitinib and VEGF antagonists (in collaboration with Frida Abel, Genomics)

We are part of Sahlgrenska Translational Neuroendocrine Cancer Group (SATNEC).

Research tools and resources

Our group has established the first human midgut carcinoid cell line (GOT 1) with maintained serotonin secretion and expression of SSTR 2&5. We have also established a human MTC cell line (GOT 2) carrying RET mutation. Both cell lines are studied as xenografts in nude mice.

Current group members

Ola Nilsson, MD, PhD, professor
Yvonne Arvidsson, PhD
Erik Elias, PhD, Med Dr
Gülay Altiparmak, technician
Linda Inge, technician

Selected publications

  1. Kölby L, Ahlman H, Wängberg B et al. A transplantable human carcinoid as model for somatostatin receptor- and amine transporter-mediated radionuclide uptake (2001) Am J Pathol 158:745-755
  2. Johanson V, Arvidsson Y, Kölby L et al. Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice (2005) Neuroendocrinology 82:171-177
  3. Johanson V, Ahlman H, Bernhardt P et al. A transplantable human medullary thyroid carcinoma as a model for tyrosine-driven tumorigenesis (2007) Endocr Relat Cancer 14:433-444
  4. Andersson E, Swärd C, Stenman G et al. High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids. Endocr Relat Cancer 16:953-966, 2009
  5. Nilsson O, Arvidsson Y, Johanson V et al. New medical strategies for midgut carcinoids (2010) Anti-Cancer Agents in Med Chem (ACA-MC) 10:250-269


More group Ola Nilsson publications on PubMed



Read more about Sahlgrenska Translational Neuroendocrine Cancer Group and its activities.

Contact information

Ola Nilsson

E-mail: Ola Nilsson
Phone: +46 (0)31 342 1000

Visiting address:
Sahlgrenska University Hospital
Gula Stråket 8
413 45 Gothenburg

Page Manager: Yael Zukovsky Fitoussi|Last update: 10/9/2019

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?